Yield of Multiplex Panel Testing Compared With Expert Opinion and Validation Prediction Models

In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.

A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.

HBI0101, an academically sourced CAR T-cell therapy, demonstrated a high objective response rate and manageable safety in patients with relapsed/refractory multiple myeloma.

Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.

In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.